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Fluorescent macrolide probes – synthesis
and use in evaluation of bacterial resistance†
M. Rhia L. Stone, a Urszula Łapińska, b Stefano Pagliara, b Muriel Masi, c
Joanne T. Blanchfield, d Matthew A. Cooper a and Mark A. T. Blaskovich *a
The emerging crisis of antibiotic resistance requires a multi-pronged approach in order to avert the
onset of a post-antibiotic age. Studies of antibiotic uptake and localisation in live cells may inform the
design of improved drugs and help develop a better understanding of bacterial resistance and
persistence. To facilitate this research, we have synthesised fluorescent derivatives of the macrolide
antibiotic erythromycin. These analogues exhibit a similar spectrum of antibiotic activity to the parent
drug and are capable of labelling both Gram-positive and -negative bacteria for microscopy. The probes
localise intracellularly, with uptake in Gram-negative bacteria dependent on the level of efflux pump
activity. A plate-based assay established to quantify bacterial labelling and localisation demonstrated that
the probes were taken up by both susceptible and resistant bacteria. Significant intra-strain and -species
differences were observed in these preliminary studies. In order to examine uptake in real-time, the probe
was used in single-cell microfluidic microscopy, revealing previously unseen heterogeneity of uptake in
populations of susceptible bacteria. These studies illustrate the potential of fluorescent macrolide probes to
characterise and explore drug uptake and efflux in bacteria.
Introduction
Macrolide antibiotics are a natural product-class of drugs
discovered in the mid-twentieth century following isolation
from bacteria such as Saccharopolyspora erythrea. The arche-
typal macrolide, erythromycin (1, Fig. 1), entered clinical use in
1952. Since then, more than 10 semi-synthetic macrolides (e.g.
roxithromycin 2 and azithromycin 3, Fig. 1) have been devel-
oped and now see wide-spread clinical use.1
Macrolides are generally active against Gram-positive and
-negative cocci (e.g. Staphylococci, Streptococci, Neisseria
meningitidis), Gram-positive and some -negative bacilli (e.g.
Bacilli, Bordatella), atypical bacteria (e.g. Mycobacterium avium
complex, Helicobacter pylori), and intracellular pathogens (e.g.
Legionella, Chlamydia).2 One factor increasingly limiting their
use is acquired macrolide resistance, which was observed only a
few years after their introduction into the clinic.1 Resistance to the
macrolides falls into one of four mechanistic categories: modifi-
cation of the macrolide target (the 50 s subunit of the bacterial
ribosome); target protection (removal of macrolide from the active
site); macrolide efflux (reduces intracellular concentration); or
Fig. 1 Common macrolide antibiotics erythromycin 1, roxithromycin 2,
azithromycin 3, and generic probe structure 4.
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antibiotic modification.3 Chief amongst these mechanisms are
ribosome modifications effected by the erm (erythromycin
ribosome methylation) enzymes, which mono- or di-methylate
the ribosome, interfering with macrolide binding; and the mef
and mrs efflux pumps, which decrease intracellular concentra-
tions of the antibiotic via active export.1 Many pathogenic
bacteria in the clinic now possess one or more of these
resistance mechanisms, with their dissemination between bac-
teria facilitated by plasmid transmission.4
In order to combat macrolide resistance and develop new
therapies for resistant bacteria, we need better tools to improve
our understanding of drug mode of action and resistance
mechanisms, especially in terms of drug accumulation and
efflux. One set of tools that have found increasing utility in
antibiotic resistance research are fluorescent antibiotics.5
Although innately fluorescent or fluorescent analogues of anti-
biotics were used in the second half of the 20th century to
investigate the mode of action of antibiotics,5 they have been
applied sparingly to help address the modern crisis of resis-
tance. Examples of probes that have been successfully utilised
include fluorescent glycopeptides6 and b-lactams.7–9 However,
instead of phenotypic studies, characterisation of resistance
has shifted towards – omics studies, where changes at the
genetic, epigenetic and transcriptomic levels are analysed.5
Where intracellular distribution studies have been conducted,
they have largely relied on radioactive analogues, which are
costly, difficult to access, and require specialist equipment.10–19
Neither of these techniques readily allow for analysis at
single-cell resolution, though some single cell sequencing
reports are beginning to appear.20,21 Despite the success of
these approaches, there remains a significant appeal in simple
tools that are readily accessible and do not require a large
time or resource investment, or which can be utilised in
combination with more modern technology, such as high-
resolution microscopy and single cell microfluidics.
There have been several fluorescent macrolides reported in
the literature, however none of these have seen widespread
use. In the 1970s, Pestka and colleagues used a fluorescein-
erythromycin conjugate to study interactions with the
ribosome,22,23 and were able to determine which subunit the
probe bound to, along with information about the binding
kinetics. These assays were carried out on isolated ribosomes,
so it is unclear how the fluorescent macrolide behaved in live
bacteria. This is a common flaw with many antibiotic-derived
probes – their antibacterial activity is often not reported and the
degree of cell penetration unknown.5 With the fluorescein substi-
tuent being a moderate-sized ligand on its own (M = 332 g mol1), it
is likely that it would interfere with entry of the conjugate into
the cell. Three decades later, Li et al. developed boron-
dipyrromethene (BODIPY)-erythromycin probes that were also
used to study interactions at the ribosome.24 Again, antibacter-
ial activity was not measured, so it is unclear how effectively
these probes mimic the parent antibiotic. The authors used the
fluorescent macrolide to develop a high-throughput screening
protocol to identify new antibiotic candidates. More recently,
Matijasic et al. reported several azithromycin-based fluorescent
compounds (with a 7-nitrobenz-2-oxa-1,3-diazol-4-yl (NBD)
fluorophore), which were used to evaluate azithromycin dis-
tribution in mammalian cells and whole animals.25 Alone of
the previously reported fluorescent macrolides, those prepared
by Matijasic et al. were confirmed to retain the antibacterial
activity of the parent drug, a critical step in ensuring that
the probe accurately represents the parent in studies. However,
neither uptake nor localisation in bacterial cells was assessed
in their work. To date, no work has been reported utilising
fluorescent macrolides for studying antibiotic resistance;
indeed there are relatively few reports on the use of any
macrolide-derived fluorescent probes.26 In order to address
this gap, in this paper we report on the synthesis and character-
isation of two novel fluorescent derivatives of erythromycin, where
a common antibiotic core is linked to two different fluorophores.
We assessed their activity against both Gram-positive and Gram-
negative bacteria, showing that both probes retained good to
moderate levels of antimicrobial activity. In order to assess their
utility for the study of antibiotic-bacterial interactions, particularly
investigations of resistance mechanisms, we tested their ability to
label bacteria using a combination of spectrofluorometry and
microscopy, at both single cell and bulk population levels.
For bulk measurements we used spectrophotometry,
because this technique is especially useful for quantitative
analysis. It is fast, inexpensive, readily available, and compa-
tible with plate-based, high-throughput assays, and allowed us
to investigate antimicrobial resistance at the ensemble level.
We also employed high-resolution microscopy to gain a more
detailed view of interactions between bacteria and the probes
at a single cell level. We then bridged both techniques with
single-cell microfluidics, where we again gained insights into
antimicrobial resistance at the single cell level but were able to
simultaneously monitor thousands of individual cells.
Results and discussion
Synthesis
We utilised the same strategy that we have previously applied to
functionalise other antibiotics,27–29 whereby we first installed
an azide ‘handle’ to which different fluorophores can be readily
attached using a copper activated azide–alkyne cycloaddition
(CuAAC) reaction. This reaction is highly selective, compatible
with unprotected functional groups, and yields a stable, bio-
compatible triazole linker. A key component of this tactic is to
select a site for modification that does not perturb the anti-
bacterial activity. Although several macrolide sites have been
modified in the literature, the ketone at the 9-position of
erythromycin was selected as the point of attachment due to
the simple, high-yielding procedures available (4, Fig. 1). This
ketone has been observed to not make significant interactions
with the ribosomal active site in crystal structure studies.30
To this end, erythromycin 1 was treated with hydroxylamine
to yield oxime 5 in quantitative yield (Scheme 1).31 A linker was
then installed by alkylation with 1-bromo-4-chlorobutane.
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Substitution of the terminal halide with sodium azide, yielding
roxi-C4–N3 6 in 25% yield from the oxime.
With azide 6 in hand, azide–alkyne click reactions were
carried out using alkyne-fluorophores 7 and 8 derived from
NBD and 7-dimethylaminocoumarin-4-acetic acid (DMACA)
respectively, to form fluorescent macrolides 9 (roxi-C4-Tz-NBD)
and 10 (roxi-C4-Tz-DMACA) in moderate yields (Scheme 2). Ele-
vated temperature was required to facilitate dissolution, and the
modest isolated yields (36–37%) were due to product losses
during purification on a small scale, rather than incomplete
reaction. The NBD and DMACA fluorophores were chosen due
to their relatively small size (molecular weight of fluorophore only
165 and 231 g mol1 respectively) compared to other fluorophores
such as fluorescein, BODIPY-FL, or rhodamine B (fluorophore
MW of 316, 276 and 463 g mol1 respectively). The smaller
substituent size reduces the likelihood that attaching it to the
antibiotic core will reduce bacterial uptake of the conjugate.
Furthermore, conjugation of the NBD fluorophore was found
to not impair biological activity for azithromycin,25 hence
was considered a promising candidate for attachment by click
chemistry.
Antibacterial activity
In order to confirm that the fluorescent probes 9 and 10 retained
the antibiotic activity of the parent drug, minimum inhibitory
concentrations (MICs) were measured against a panel of sus-
ceptible bacteria (Table 1). Here, roxi-C4–N3 6 displayed good to
excellent antibacterial activity against all Gram-positive cocci
Scheme 1 Synthesis of roxithromycin-azide 6 from erythromycin 1, via formation of oxime intermediate 5, which is then O-alkylated with 1-bromo-4-
chlorobutane, followed by displacement of the terminal halide with azide.
Scheme 2 Synthesis of fluorescent macrolides 9 and 10 from azide 6 and fluorophore-alkynes 7 and 8.
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and bacilli tested, with MICs generally at most 8-fold less
potent compared to the parent drugs erythromycin 1 and
roxithromycin 2. Similarly, NBD probe 9 exhibited good to
moderate antibacterial activity, with very similar activity as
the azide 6 against Staphylococci and Streptococci (e.g. 4- to
8-fold less active than the parent roxithromycin). The DMACA
probe 10 was also active at inhibiting bacterial growth, though
was less potent than the other derivatives tested, with approxi-
mately 4- to 16-fold increased MIC compared to the NBD probe.
However, both probes showed similar relative changes in
potency across the different strains tested as the parent anti-
biotic. For example, consistent with the lack of activity of
erythromycin and roxithromycin (MIC Z 64 mg mL1), none
of the macrolide probes showed substantial inhibitory activity
against the one Gram-negative species tested, Escherichia coli
(E. coli).
A panel of resistant Streptococci with either defined
(erm(B)+, mef(e)+) or undefined mechanisms of resistance were
then tested (Table 2). The Streptococcus pneumoniae (S. pneu-
moniae) strains were found to be highly resistant to all the
macrolides tested, with MICs of Z64 mg mL1 recorded. This
was also the case for S. pyogenes ATCC BAA-1412, however the
MICs against ATCC BAA-1414 were only mildly elevated (still
above breakpoint for roxithromycin 2).32 Overall, the azide
intermediate and fluorescent probes had similar antibiotic
activity profiles as compared to the parent drugs, with greatly
increased MICs against the macrolide-resistant bacteria. The
MIC values were used to inform appropriate concentrations for
subsequent assays.
Intracellular labelling and localisation
With antibiotic activity established, live-cell confocal micro-
scopy was performed in S. aureus and susceptible and resistant
Streptococci to examine localisation and labelling and
gain insight about the macrolide resistance mechanisms in
resistant Streptococci strains. Bacteria were incubated with
fluorescent probes 9 and 10, along with the red membrane
dye FM4-64FX and a complementary nucleic acid dye (Syto-9,
green; or Hoechst-33342, blue). Despite its reduced antibacter-
ial potency, Roxi-C4-Tz-DMACA 10 was found to provide super-
ior labelling for microscopy and was able to be used at
concentrations as low as 1 nM in some species. The reason
for this difference from NBD probe 9 is unclear but given the
similarity in MIC (Tables 1 and 2) and uptake results from the
quantitative assays (see Fig. 5, 7 and Table 3 below), the results
obtained from 10 should be representative of both probes, and
the parent antibiotic. Susceptible strains of Staphylococcus
aureus (S. aureus) and S. pneumoniae were first examined
(Fig. 2), with S. pyogenes (Fig. S1, ESI†) showing similar results,
where it was found that 10 localised intracellularly. This is in
contrast to the fluorophore-alkynes, which did not significantly
accumulate in the bacteria (Fig. S2, ESI†).
After confirming that the macrolide probe 10 successfully
reached the bacterial cytoplasm in susceptible strains, we
analysed its localization in resistant S. pyogenes and S. pneumo-
niae. Surprisingly, we found that 10 was again found to localise in
the cytoplasm (Fig. 3 and Fig. S5, ESI†), including in mef(e)+
S. pneumoniae. The latter strain, equipped with upregulated
mef efflux pumps, appeared to show patterns of localised intensity
Table 1 Minimum inhibitory concentrations (MICs, in mg mL1) of erythromycin (1), roxithromycin (2), roxi-C4–N3 (6), roxi-C4-Tz-NBD (9), and roxi-C4-
Tz-DMACA (10) against a panel of American Type Culture Collection (ATTC) susceptible bacteria, measured by broth microdilution in cation-adjusted
Mueller Hinton broth (CAMHB), n Z 4
Species Strain Ery 1 Roxi 2 Roxi-N3 6 Roxi-NBD 9 Roxi-DMACA 10
S. aureus ATCC25923 0.25–0.5 0.25–2 1–4 1–4 8–16
S. epidermidis ATCC12228 0.25–1 0.5–1 0.031–0.063 0.5–1 16–64
S. pneumoniae ATCC33400 0.25–0.5 0.5–2 1–2 1–2 8–32
S. pyogenes ATCC12344 r0.016 r0.016 r0.016 0.031–0.063 0.13
E. faecium ATCC35667 0.25–2 1–8 2–8 16 64
B. subtilis ATCC6051 0.13–0.25 0.25–2 0.5–1 1–2 8 -16
E. coli ATCC25922 64 Z64 Z64 Z64 Z64
AG102a Z64 Z64 Z64 Z64 Z64
a mar1, upregulated Acr-AB efflux pump.
Table 2 Minimum inhibitory concentrations (MICs, in mg mL1) of erythromycin (1), roxithromycin (2), roxi-C4–N3 (6), roxi-C4-Tz-NBD (9), and roxi-C4-
Tz-DMACA (10) against a panel of susceptible (for comparison) and resistant Streptococci, measured by broth microdilution in brain-heart infusion (BHI),
n Z 3
Species Strain Ery 1 Roxi 2 Roxi-N3 6 Roxi-NBD 9 Roxi-DMACA 10
S. pneumoniae ATCC 33400 0.25–0.5 0.25–2 1–4 1–4 8–16
ATCC 700677a Z64 16–Z64 16–Z64 4–Z64 8–Z64
ATCC 700676bc Z64 Z64 Z64 Z64 Z64
S. pyogenes ATCC 12344 r0.016 r0.016 r0.016 0.031–0.063 0.13
ATCC BAA-1412 Z64 Z64 Z64 Z64 Z64
ATCC BAA-1414 0.031–0.13 1–2 0.063–1 r0.016–0.063 1
a erm(B)+. b mef(e)+. c 5% CO2.
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when compared to the corresponding susceptible strain, but still
had substantial internal labelling. In order to assess whether this
difference in labelling was due to increased efflux in the resistant
strain, samples were incubated with the protonophore carbonyl
cyanide m-chlorophenylhydrazine (CCCP), which acts by disabling
the proton motive force driving efflux pumps.33 In this case we
found no change in the localisation or intensity of labelling
compared to the susceptible strain ATCC 33400.
Dynamics of intracellular accumulation
Although confocal microscopy allows for observation of the
precise intracellular localisation of the macrolide probes, it is
not suitable for quantifying the dynamics of antibiotic accu-
mulation in individual bacteria. Therefore, we complemented
the measurements above with studies carried out using our
previously established single-cell microfluidics-microscopy
assay.34–37 This technique enables single-cell studies to address
the impact of phenotypic heterogeneity38,39 on intracellular
drug accumulation and efficacy.40,41 As a proof of concept, we
examined the real-time uptake of roxi-C4-Tz-NBD 9 into E. coli
(BW25113, a K12 strain) and susceptible S. aureus (MSSA476).
Here it was found that the probe was rapidly taken up by
S. aureus cells, with uptake initiated near-simultaneously across
all measured cells, although there was significant variation in
the speed and extent of uptake (Fig. 4A). In contrast, there was a
long lag period before any E. coli became fluorescent (Fig. 4B).
Even when the E. coli did take on the probe, both initiation and
rate of uptake showed a substantial variability in response.
The spread of fluorescence behaviour indicates that in both
Fig. 2 Confocal microscopic images of (A–D) live susceptible S. aureus (ATCC 25923) and (E–H) susceptible S. pneumoniae (ATCC 33400) labelled
with (A and E) roxi-C4-Tz-DMACA 10 (10 mM); (B and F) Syto-9 (green nucleic acid dye, 5 mM); (C and G) FM4-64FX (red membrane dye, 5 mg mL
1); and
(D and H) overlaid.
Fig. 3 Confocal microscopic images of (A–D) live resistant S. pyogenes (ATCC BAA-1412) and (E and F) resistant S. pneumoniae (ATCC 700676) labelled
with (A and E) roxi-C4-Tz-DMACA 10 (10 mM); (B and F) Syto-9 (green nucleic acid dye, 5 mM); (C and G) FM4-64FX (red membrane dye, 5 mg mL
1); and
(D and H) overlaid.
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species examined, there is inherent population variability in
response to the roxi-NBD probe 9. For E. coli, there were also
cells which did not accumulate any probe, despite being
surrounded by bacteria with substantial uptake (see Fig. 4E
and F, e.g. right hand panels, third channel, 2nd bacterium
from the bottom is visible in the brightfield microscopy image,
but is not fluorescent despite cells on either side with high
levels of fluorescence). The intracellular variation is striking.
This suggests heterogeneity in the macrolide response, poten-
tially due to differences in levels of native efflux pumps or in
the abundance of ribosomes that are the intracellular targets of
macrolides, or a quiescent subpopulation. These new probes
and time-dependent data open the way for deepening our
understanding of subsets of bacteria, including persister and
viable but non culturable cells,40,42 that can transiently survive
antibiotic exposure and contribute to recalcitrant infections43
and the development of antibiotic resistance.44
Dynamics of efflux
In order to gain further insight on the molecular mechanisms
underlying reduced intracellular accumulation of our macro-
lide probes, we used ensemble measurements to quantify
efflux, one of the major forms of resistance to macrolides.
We hoped that the macrolide probes could be used as tools
to identify efflux upregulation in resistant bacteria, study this
mode of resistance, and help guide the development of strate-
gies to overcome efflux.
To start the examination of bacterial efflux of fluorescent
macrolides 9 and 10, the model organism E. coli AG102 was
used, in which efflux pump AcrAB is overproduced (mar1
mutant). In order to assess whether the roxi-probes were
subject to efflux in this model, intracellular accumulation was
measured by spectrophotometry over time in the presence
and absence of CCCP (Fig. 5). Mid-log phase bacteria were
incubated with the macrolide probes (with or without CCCP),
with aliquots withdrawn at each time point. Labelled bacteria
were then collected and lysed overnight using glycine-HCl. The
lysed bacteria were centrifuged, and the fluorescence of the
decantate measured using a plate reader. As expected, neither
roxi-C4-Tz-NBD 9 or roxi-C4-Tz-DMACA 10 showed significant
internalisation into AG102 in the absence of CCCP. In contrast,
both probes showed a time-dependent accumulation when efflux
was abolished. This finding indicates both that the fluorescent
macrolides are indeed efflux pump substrates (potentially the
AcrAB pump in this strain of E. coli) and their internal accumula-
tion can be used as a marker for the presence of efflux.
To confirm this, live cell microscopy was carried out with
AG102 incubated with roxi-C4-Tz-DMACA 9 with or without
CCCP (Fig. 6). Here, the same pattern of labelling was observed,
with the efflux-active cells not showing significant uptake of the
probe, but CCCP-treated efflux-negative cells having considerable
Fig. 4 Accumulation of roxi-C4-Tz-NBD 9 in susceptible S. aureus (MSSA476) (A–C) and E. coli (BW25113) (D–F) cells as monitored by single-cell
microfluidics over time. Fluorescence of individual cells is tracked in (A and D), with the average shown in bold with symbols. Times of snapshots (B, C and
E, F) are indicated with dashed vertical lines. Brightfield (B and E) and the corresponding fluorescent (C and F) images are shown at early (2200 and
4000 s) and late (4400 and 12 000 s) timepoints for both species.
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internal probe fluorescence. Gratifyingly, this lack of significant
labelling in efflux-active E. coli qualitatively corroborates the
single-cell data concerning the dynamics of macrolide accumula-
tion presented in Fig. 4. Although eventual uptake was seen in
microfluidic analysis, this was not until after 80 min, whereas the
microscopy samples were only incubated with probes for 30 min.
Quantification of intracellular labelling
In order to quantitatively evaluate intracellular labelling in a
high-throughput bulk-population measurement, a plate- based
assay was developed using S. aureus, S. pneumoniae, and
S. pyogenes, building on existing work in the literature.45
Bacteria were grown to mid-log phase, then treated with probes
9 or 10, along with controls of alkynes 7 and 8, and roxithro-
mycin 2. Aliquots were taken of this incubation mixture, which
was then centrifuged. Another aliquot was taken of the super-
natant, which contained excess probe not taken up by the
bacteria (Fig. 7). The bacteria were then washed, and portions
of both the wash decantate (containing loosely bound probe
that could be washed off, or probe that may have been rapidly
effluxed after uptake) and the washed bacteria were taken for
sampling (see ESI† for more detail). Finally, the remaining
washed bacteria were lysed using lysozyme, detergent (bacterial
protein extraction reagent, B-PER) and freeze-thawing, then
centrifuged to separate the intracellular fluid (IF) (e.g. with any
free probe inside the bacteria) from the remaining pellet (with
probe bound to cell membrane or intracellular components).
All fractions were then assessed for fluorescence. In order to
transform the raw data into meaningful values, several normal-
isations were conducted (see ESI†). At the 1 mM concentration
Fig. 5 Intracellular accumulation of macrolide probes with NBD 9 (A) and DMACA 10 (B) fluorophores (50 mM) in AG102 E. coli in the absence and
presence of efflux inhibitor CCCP (10 mM), n = 3, * = p o 0.05, ** = p o 0.01.
Fig. 6 Airyscan confocal microscopy of AG102 E. coli without (A–C) or with (D–F) treatment with 10 mM CCCP: (A and D) DMACA probe 10 (5 mM),
(B and E) FM4-64FX (red membrane stain), and (C and F) overlaid.
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used in the assay (B1 mg mL1), roxi-C4-Tz-DMACA 10 was
found to mostly elute in the excess probe aliquot, indicating
this is beyond the saturation limit of the bacteria (Fig. 6). Given
that the concentration to which the bacteria were exposed is
around (susceptible) or below (resistant) the MIC, it indicates
that uptake is a significant limiting factor in antibacterial
activity. The next step, washing, did not lead to significant
loss of fluorescence, showing that once absorbed, the probe is
not readily removed. As similarly low fluorescence levels were
seen in the wash of efflux active strains, it can be inferred that
substantial macrolide efflux does not occur over this time-
frame. From the whole washed bacteria (medium blue bars in
Fig. 6), lysis revealed that the probe fluorescence was primarily
localised in the intracellular fluid, rather than bound to cellular
debris in the pellet fraction. This is consistent with the probes
targeting the ribosomes, which are normally located in the
intracellular fluid. The labelling and localisation of roxi-C4-Tz-
NBD 9 proved to be very similar to its DMACA counterpart 10
(Fig. S4, ESI†). As before, most of the fluorescence was observed in
the excess aliquot, though this was less prominent in S. pyogenes,
possibly due to increased uptake of the NBD probe. Fluorophore
alkynes 7 and 8 were also tested as controls, but they washed off
the bacteria with practically no uptake from the full to whole
aliquots, confirming that the roxithromycin fluorescent probes
are acting in a target specific fashion (Fig. S4, ESI†).
In order to quantify the uptake of the probes, we calculated
the percentage of the (reconstructed) full signal that ended up
in the intracellular fluid (for details see ESI†). The percentage of
probe taken up by the bacteria was found to be highly variable
between different species, ranging from 2% of the total added
in susceptible S. aureus to as much as 50% in S. pyogenes
(Table S6, ESI†). In general, the values obtained for the two
fluorescent macrolide probes were similar, and in contrast the
fluorophore-alkynes showed very little uptake in any of the
bacteria tested.
As mentioned previously, the macrolide probes localised in
the cytosol. Of the combined cytosol and pellet fluorescence
obtained after lysis, the IF portion contributed greater than
75% in most cases (Table 3). The percentages for roxi-C4-Tz-
DMACA 10 and roxi-C4-Tz-NBD 9 were generally very compar-
able in S. aureus and S. pneumoniae, but in S. pyogenes the NBD
probe 9 consistently showed lower levels of accumulation,
indicating a potential species-selective bias between the NBD
vs. DMACA probes.
Comparing the macrolide sensitive and resistant Strepto-
cocci, contrasting trends were again observed between S. pyo-
genes and S. pneumoniae. ATCC BAA-1412 resistant S. pyogenes
showed a reduced fluorescence in the IF aliquot, potentially
indicating less of an attraction for this subcellular localisation.
In contrast, the mef(e)+ S. pneumoniae ATCC 700676 showed a
Fig. 7 Scaled fluorescence of roxi-C4-Tz-DMACA 10 in aliquots (incubation mixture, excess probe, wash media, whole bacteria, intracellular fluid,
pellet) of different bacteria: susceptible S. aureus and susceptible S. pyogenes and S. pneumoniae.
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somewhat increased preference for localisation of the probe
in the IF compared to the susceptible strain (Table 3) and a
similar overall uptake (IF and pellet, Fig. S2, ESI†), an unex-
pected result given that greater efflux should lead to reduced
intracellular levels, if the efflux is responsible for the macrolide
resistance. However, the result is consistent with the uptake
seen in confocal microscopy (Fig. 3 vs. Fig. 2), suggesting
that the macrolide probe may not actually be a substrate for
the S. pneumoniae efflux pumps, with the higher MIC due to an
alternative resistance mechanism.
These results, albeit preliminary, illustrate the power of this
assay in generating data on the localisation of antibiotics, especially
when applied to investigations of resistance. Combining qualitative
high-resolution fluorescence microscopy with quantitative
single-cell and bulk-population methods and mechanistic-
specific fluorescent probes can provide a rich understanding
of the chemical biology of the interactions between bacteria
and antibiotics.
Conclusion
Two novel fluorescent derivatives of roxithromycin have been
synthesised from erythromycin, via site-selective modification
to add an azide substituent which was then utilised for azide–
alkyne ‘click’ chemistry to link two different colour fluoro-
phores with an alkyne substituent. The resultant probes
retained the same pattern of antibiotic activity as the parent
drugs, and labelled both Gram-positive and -negative bacteria
when visualised by confocal microscopy. Fluorescence was
observed to be localised inside the bacteria, with greatly increased
uptake observed in efflux-inhibited Gram-negative bacteria.
However, reduced uptake was not seen in efflux upregulated
Gram-positive bacteria. In order to examine the dynamics of the
accumulation of these probes, single-cell microfluidics was
used, revealing significant heterogeneity within populations
that may relate to persistence and/or resistance. Lastly, uptake
was quantified on the bulk-scale by a plate-based assay. The
probes were taken up by the bacteria and mostly localised in
the intracellular fluid. Significant differences were seen between
different species and strains, with unexpected trends in some
strains with upregulated efflux, indicating scope for future work.
This preliminary work illustrates the potential utility of the
macrolide fluorescent probes in illuminating the interactions
between antibiotics and bacteria, providing new insight into
mechanisms of resistance. Fluorescent probes enable the
researcher to visualise target interactions in a practical manner,
and can be applied to experiments that range from studies of
isolated targets through to investigations of mixed populations.
Future implications include quantitatively distinguishing
modes of macrolide resistance and uncovering heterogeneity
in antibiotic response amongst bacterial populations.
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